Asociación Mexicana de Hepatología A.C. Guía Clínica de Hepatitis B

Organización Mundial de la Salud. Hepatitis B [consultado 13 Dic 2019] Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/hepatitis-b; 19 de Julio de 2019 Marín-López, 2005, Primer consenso nacional de hepatitis B crónica, Rev Gastroenterol Mex, 70, 490 Manterola, 2014, Jerarquía de evidencia: Niveles de evidencia y grados de recomendación de uso actual, Rev Chilena Infectol, 31, 705, 10.4067/S0716-10182014000600011 Medina-Rojo, 2017, National prevalence of hepatitis C and B viruses in Mexican blood donors, 2000-2012, Rev Med Hosp Gen Mex, 80, 37 Panduro, 2011, Epidemiología de las hepatitis virales en México, Salud Publica Mex, 53, S37 Sanchez, 2002, Genotypes and S-gene variability of Mexican hepatitis B virus strains, J Med Virol, 68, 24, 10.1002/jmv.10166 Panduro, 2013, Distribution of HBV genotypes F and H in Mexico and Central America, Antivir Ther, 18, 475, 10.3851/IMP2605 Roman, 2013, HBV endemicity in Mexico is associated with HBV genotypes H and G, World J Gastroenterol, 19, 5446, 10.3748/wjg.v19.i33.5446 Roman, 2010, Occult Hepatitis B in the genotype H-infected Nahuas and Huichol native Mexican population, J Med Virol, 82, 1527, 10.1002/jmv.21846 Fierro, 2011, Multiple cytokine expression profiles reveal immune-based differences in occult hepatitis B genotype H-infected Mexican Nahua patients, Mem Inst Oswaldo Cruz, 106, 1007, 10.1590/S0074-02762011000800018 Román, 2013, Hepatitis B virus genotype H and environmental factors associated to the low prevalence of hepatocellular carcinoma in Mexico, J Cancer Ther, 4, 367, 10.4236/jct.2013.42A044 Román, 2014, Hepatitis B virus infection in Latin America: A genomic medicine approach, World J Gastroenterol, 20, 7181, 10.3748/wjg.v20.i23.7181 Croagh, 2014, Natural history of chronic hepatitis B: Phases in a complex relationship, World J Gastroenterol, 20, 10395, 10.3748/wjg.v20.i30.10395 Schillie, 2018, Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR Recomm Rep, 67, 1, 10.15585/mmwr.rr6701a1 Ganem, 2004, Hepatitis B virus infection-natural history and clinical consequences, N Engl J Med, 350, 1118, 10.1056/NEJMra031087 Valdespino, 2007, Prevalencia en México de la infección y el estado de portador de la hepatitis B en adultos, Salud Publica Mex, 49, S404, 10.1590/S0036-36342007000900012 Zanella, 2020, Hepatitis B seroprevalence in the pediatric and adolescent population of Florence (Italy): An update 27 years after the implementation of universal vaccination, Vaccines (Basel), 8, 156, 10.3390/vaccines8020156 Gehring, 2016, The role of innate immunity in the immunopathology and treatment of HBV infection, J Hepatol, 64 Bertoletti, 2016, Adaptive immunity in HBV infection, J Hepatol, 64, S71, 10.1016/j.jhep.2016.01.026 Hoofnagle, 2009, Reactivation of hepatitis B, Hepatology., 49, S156, 10.1002/hep.22945 2012, EASL clinical practice guidelines: Management of chronic hepatitis B virus infection, J Hepatol., 57, 167, 10.1016/j.jhep.2012.02.010 2017, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection, J Hepatol., 67, 370, 10.1016/j.jhep.2017.03.021 Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Baecker, 2018, Worldwide incident hepatocellular carcinoma cases attributable to major risk factors, Eur J Cancer Prev, 27, 205, 10.1097/CEJ.0000000000000428 Sun, 2012, Obesity, inflammation, and liver cancer, J Hepatol., 56, 704, 10.1016/j.jhep.2011.09.020 Tan, 2019, Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: A meta-analysis and systematic review, Cancer Manag Res, 11, 705, 10.2147/CMAR.S188238 Miele, 2015, Diabetes and insulin therapy, but not metformin, are related to hepatocellular cancer risk, Gastroenterol Res Pract, 2015, 570356, 10.1155/2015/570356 Bréchot, 1980, Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma, Nature, 286, 533, 10.1038/286533a0 Bréchot, 2004, Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: Old and new paradigms, Gastroenterology, 127, S56, 10.1053/j.gastro.2004.09.016 Murakami, 2005, Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas, Gut, 54, 1162, 10.1136/gut.2004.054452 Yang, 2002, Hepatitis B e antigen and the risk of hepatocellular carcinoma, N Engl J Med, 347, 168, 10.1056/NEJMoa013215 Chen, 2006, Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 65, 10.1001/jama.295.1.65 Tseng, 2012, High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load, Gastroenterology, 142, 1140, 10.1053/j.gastro.2012.02.007 Lin, 2018, Review article: The prevention of hepatitis B-related hepatocellular carcinoma, Aliment Pharmacol Ther, 48, 5, 10.1111/apt.14683 Papatheodoridis, 2011, Gut, 60, 1109, 10.1136/gut.2010.221846 Farinati, 2006, Diagnostic and prognostic role of a-fetoprotein in hepatocellular carcinoma: Both or neither?, Am J Gastroenterol, 101, 524, 10.1111/j.1572-0241.2006.00443.x Figueras, 2001, Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: Results of a multicenter study, Liver Transpl, 7, 877, 10.1053/jlts.2001.27856 Yao, 2001, Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival, Hepatology, 33, 1394, 10.1053/jhep.2001.24563 Coli, 2006, Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: A systemic review, Am J Gastroenterol, 101, 513, 10.1111/j.1572-0241.2006.00467.x Hemming, 2016, Hepatitis B and hepatocellular carcinoma, Clin Liv Dis, 20, 703, 10.1016/j.cld.2016.06.007 Iida-Ueno, 2017, Hepatitis B virus infection and alcohol consumption, World J Gastroenterol, 23, 2651, 10.3748/wjg.v23.i15.2651 Ribes, 2006, Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up, Int J Cancer, 119, 687, 10.1002/ijc.21882 Rehm, 2010, Alcohol as a risk factor for liver cirrhosis: A systematic review and meta-analysis, Drug Alcohol Rev, 29, 437, 10.1111/j.1465-3362.2009.00153.x Jarcuska, 2016, Association between hepatitis B and metabolic syndrome: Current state of the art, World J Gastroenterol, 22, 155, 10.3748/wjg.v22.i1.155 Razi, 2017, Association of chronic hepatitis B infection with metabolic syndrome and its components: Meta-analysis of observational studies, Diabetes Metab Syndr, 11, S939, 10.1016/j.dsx.2017.07.020 Kasmari, 2017, Independent of cirrhosis, hepatocellular carcinoma risk is increased with diabetes and metabolic syndrome, Am J Med, 130, 746.e1, 10.1016/j.amjmed.2016.12.029 Reiss, 2004, Review article: Hepatitis vaccination in patients with chronic liver disease, Aliment Pharmacol Ther, 19, 715, 10.1111/j.1365-2036.2004.01906.x Rojas-Cordero, 2008, Cuantificación del virus de Hepatitis B por la técnica PCR tiempo real, Acta Med Costarricense, 50, 11 Iloeje, 2006, Predicting cirrhosis risk based on the level of circulating hepatitis B viral load, Gastroenterology, 130, 678, 10.1053/j.gastro.2005.11.016 Block, 2013, Chronic hepatitis B: What should be the goal for new therapies?, Antiviral Res, 98, 27, 10.1016/j.antiviral.2013.01.006 Hatzakis, 2011, The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference, J Viral Hepat, 18, S1, 10.1111/j.1365-2893.2011.01499.x MacLachlan, 2012, Liver cancer is the fastest increasing cause of cancer death in Australians, Med J Aust, 197, 492, 10.5694/mja12.11481 Mitchell, 2010, Institute of Medicine recommendations for the prevention and control of hepatitis B and C, Hepatology, 51, 729, 10.1002/hep.23561 Perumalswami, 2013, Hepatitis outreach network: A practical strategy for hepatitis screening with linkage to care in foreign-born communities, J Hepatol, 58, 890, 10.1016/j.jhep.2013.01.004 Vedio, 2013, Hepatitis B: Report of prevalence and access to healthcare among Chinese residents in Sheffield UK, J Infect Public Health, 6, 448, 10.1016/j.jiph.2013.05.004 Martinot-Peignoux, 2015, HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients, Liver Int, 35, S82, 10.1111/liv.12735 Seto, 2013, Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy, Hepatology, 58, 923, 10.1002/hep.26376 Tian, 2016, Hepatitis B virus genotypes: Epidemiological and clinical relevance in Asia, Hepatol Int, 10, 854, 10.1007/s12072-016-9745-2 Yapali, 2014, Management of hepatitis B: Our practice and how it relates to the guidelines, Clin Gastroenterol Hepatol, 12, 16, 10.1016/j.cgh.2013.04.036 Agbim, 2019, Non-invasive assessment of liver fibrosis and prognosis: An update on serum and elastography markers, Expert Rev Gastroenterol Hepatol, 13, 361, 10.1080/17474124.2019.1579641 Park, 2019, Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study, World J Gastroenterol, 25, 3256, 10.3748/wjg.v25.i25.3256 Li, 2016, Systematic review with meta-analysis: The diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B, Aliment Pharmacol Ther, 43, 458, 10.1111/apt.13488 Hako, 2019, Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B or C by contrast-enhanced magnetic resonance imaging, Can J Gastroenterol Hepatol, 2019, 3024630, 10.1155/2019/3024630 Shi, 2014, MR elastography for the assessment of hepatic fibrosis in patients with chronic hepatitis B infection: Does histologic necroinflammation influence the measurement of hepatic stiffness?, Radiology, 273, 88, 10.1148/radiol.14132592 Kim, 2016, Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients, J Hepatol, 64, 773, 10.1016/j.jhep.2015.11.012 Lemoine, 2016, The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa, Gut, 65, 1369, 10.1136/gutjnl-2015-309260 Wang, 2017, Development and validation of a model for staging hepatic fibrosis for chronic hepatitis B patients with E antigen-positive, Oncotarget, 8, 98812, 10.18632/oncotarget.22003 Lu, 2018, Assessment of liver fibrosis with the gamma-glutamyl transpeptidase to platelet ratio: A multicentre validation in patients with HBV infection, Gut, 67, 1903, 10.1136/gutjnl-2017-315299 Stasi, 2017, Non-invasive assessment of liver fibrosis in patients with HBV-related chronic liver disease undergoing antiviral treatment: A preliminary study, Eur J Pharmacol, 806, 105, 10.1016/j.ejphar.2017.03.063 Wang, 2017, A novel predictive model using routinely clinical parameters to predict liver fibrosis in patients with chronic hepatitis B, Oncotarget, 8, 59257, 10.18632/oncotarget.19501 Salkic, 2014, FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: A meta-analysis, Am J Gastroenterol, 109, 796, 10.1038/ajg.2014.21 Parikh, 2017, Fibrosis assessment in patients with chronic hepatitis B virus (HBV) infection, Ann Transl Med, 5, 40, 10.21037/atm.2017.01.28 2015, EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis, J Hepatol, 63, 237, 10.1016/j.jhep.2015.04.006 Mani, 2009, Liver biopsy findings in chronic hepatitis B, Hepatology, 49, S61, 10.1002/hep.22930 Tao, 2020, Present and future therapies for chronic hepatitis B, Adv Exp Med Biol, 1179, 137, 10.1007/978-981-13-9151-4_6 Tang, 2018, Chronic hepatitis B infection: A review, JAMA., 319, 1802, 10.1001/jama.2018.3795 Feld, 2009, Endpoints of therapy in chronic hepatitis B, Hepatology, 49, S96, 10.1002/hep.22977 Lok, 2017, Hepatitis B cure: From discovery to regulatory approval, J Hepatol, 67, 847, 10.1016/j.jhep.2017.05.008 Cornberg, 2020, Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference, J Hepatol, 72, 539, 10.1016/j.jhep.2019.11.003 Vlachogiannakos, 2018, Hepatitis B. Who and when to treat?, Liver Int, 38, S71, 10.1111/liv.13631 Peng, 2012, Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy, J Hepatol, 57, 442, 10.1016/j.jhep.2012.02.033 Cholongitas, 2015, The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis, Ann Gastroenterol, 28, 109 Lok, 2016, Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis, Hepatology, 63, 284, 10.1002/hep.28280 Jang, 2015, Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis, Hepatology, 61, 1809, 10.1002/hep.27723 Papatheodoridis, 2012, Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review, J Hepatol, 57, 196, 10.1016/j.jhep.2011.11.030 Terrault, 2018, Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance, Hepatology, 67, 1560, 10.1002/hep.29800 Chu, 2007, HBsAg seroclearance in asymptomatic carriers of high endemic areas: Appreciably high rates during a long-term follow-up, Hepatology, 45, 1187, 10.1002/hep.21612 Yip, 2017, Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance, J Hepatol, 67, 902, 10.1016/j.jhep.2017.06.019 Chayanupatkul, 2017, Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection, J Hepatol, 66, 355, 10.1016/j.jhep.2016.09.013 Yu, 2017, Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: A large cohort study, Gastroenterology, 153, 1006, 10.1053/j.gastro.2017.07.001 Yeo, 2000, Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors, J Med Virol, 62, 299, 10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0 Mori, 2015, Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations, World J Gastroenterol, 21, 10274, 10.3748/wjg.v21.i36.10274 Kanaan, 2012, Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection, J Clin Virol, 55, 233, 10.1016/j.jcv.2012.07.015 Block, 2017, Use of current and new endpoints in the evaluation of experimental hepatitis B therapeutics, Clin Infect Dis, 64, 1283, 10.1093/cid/cix129 Grek, 2016, Acute liver failure, AACN Adv Crit Care, 27, 420, 10.4037/aacnacc2016324 Wang, 2013, Advances in the management of acute liver failure, World J Gastroenterol, 19, 7069, 10.3748/wjg.v19.i41.7069 Lee, 2012, Acute liver failure, Semin Respir Crit Care Med, 33, 36, 10.1055/s-0032-1301733 Park, 2018, Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B, Dig Liver Dis, 50, 163, 10.1016/j.dld.2017.10.002 Reshef, 2000, Lamivudine in the treatment of acute hepatitis B, N Engl J Med, 34, 1123, 10.1056/NEJM200010123431513 Torii, 2002, Effectiveness and long-term outcome of lamivudine therapy for acute hepatitis B, Hepatol Res, 24, 34, 10.1016/S1386-6346(02)00009-8 Kondili, 2004, The use of lamivudine for patients with acute hepatitis B (a series of cases), J Viral Hepat, 11, 427, 10.1111/j.1365-2893.2004.00504.x Lisotti, 2008, Lamivudine treatment for severe acute HBV hepatitis, Int J Med Sci, 5, 309, 10.7150/ijms.5.309 Schmilovitz-Weiss, 2004, Lamivudine treatment for acute severe hepatitis B: A pilot study, Liver Int, 24, 547, 10.1111/j.1478-3231.2004.0983.x Tillmann, 2006, Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience, J Viral Hepat, 13, 256, 10.1111/j.1365-2893.2005.00695.x Kumar, 2007, A randomized controlled trial of lamivudine to treat acute hepatitis B, Hepatology, 45, 97, 10.1002/hep.21486 Miyake, 2008, Lamivudine treatment improves the prognosis of fulminant hepatitis B, Intern Med, 47, 1293, 10.2169/internalmedicine.47.1061 Wang, 2014, Acute liver failure caused by severe acute hepatitis B: A case series from a multi-center investigation, Ann Clin Microbiol Antimicrob, 13, 23, 10.1186/1476-0711-13-23 Streinu-Cercel, 2016, Treatment with lamivudine and entecavir in severe acute hepatitis B, Indian J Med Microbiol, 34, 166, 10.4103/0255-0857.176837 García-Alonso, 2012, Pharmacological treatment of acute hepatitis B, Med Clin (Barc), 138, 633, 10.1016/j.medcli.2011.09.026 Cai, 2019, Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naïve HBeAg-positive patients with chronic hepatitis B: A large, multicentre, randomized controlled trials, Medicine (Baltimore), 98, e13983, 10.1097/MD.0000000000013983 Lok, 2012, Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B, Gastroenterology, 143, 619, 10.1053/j.gastro.2012.05.037 Tenney, 2009, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy, Hepatology, 49, 1503, 10.1002/hep.22841 Buti, 2020, Optimal management of chronic hepatitis B patients receiving nucleos(t)ide analogues, Liver Int, 40, S15, 10.1111/liv.14367 Callebaut, 2015, In vitro virology profile of tenofovir alafenamide, a novel oral prodrug of tenofovir with improved antiviral activity compared to that of tenofovir disoproxil fumarate, Antimicrob Agents Chemother, 59, 5909, 10.1128/AAC.01152-15 Childs-Kean, 2018, Tenofovir alafenamide for the treatment of chronic hepatitis B monoinfection, Pharmacotherapy, 38, 1051, 10.1002/phar.2174 Buti, 2016, Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial, Lancet Gastroenterol Hepatol, 1, 196, 10.1016/S2468-1253(16)30107-8 Lampertico, 2020, Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: A randomised, double-blind, phase 3, multicentre non-inferiority study, Lancet Gastroenterol Hepatol, 5, 441, 10.1016/S2468-1253(19)30421-2 Yuen, 2018, Hepatitis B virus infection, Nat Rev Dis Primers, 4, 18035, 10.1038/nrdp.2018.35 Lam, 2017, Seven-year treatment outcome of entecavir in a real-world cohort: Effects on clinical parameters HBsAg and HBcrAg levels, Clin Transl Gastroenterol, 8, e125, 10.1038/ctg.2017.51 Buti, 2015, Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection, Dig Dis Sci, 60, 1457, 10.1007/s10620-014-3486-7 Jeon, 2017, Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir, Clin Mol Hepatol, 23, 230, 10.3350/cmh.2017.0003 Lee, 2017, Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance, J Viral Hepat, 24, 141, 10.1111/jvh.12623 Cho, 2015, Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance, J Med Virol, 87, 1532, 10.1002/jmv.24201 Corsa, 2014, No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B, Clin Gastroenterol Hepatol, 12, 2106, 10.1016/j.cgh.2014.05.024 Leemans, 2008, Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: Successful rescue therapy with tenofovir, Eur J Gastroenterol Hepatol, 20, 773, 10.1097/MEG.0b013e3282f793d6 Guo, 2018, Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study, Int J Antimicrob Agents, 52, 201, 10.1016/j.ijantimicag.2018.04.002 Liu, 2016, Hepatitis B: Treatment choice and monitoring for response and resistance, Expert Rev Gastroenterol Hepatol, 10, 697, 10.1586/17474124.2016.1145547 Park, 2019, Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients, J Hepatol, 70, 1093, 10.1016/j.jhep.2019.02.006 Yim, 2018, Switching to tenofovir vs continuing entecavir for hepatitis B virus with partial virologic response to entecavir: A randomized controlled trial, J Viral Hepat, 25, 1321, 10.1111/jvh.12934 Gish, 2012, Selection of chronic hepatitis B therapy with high barrier to resistance, Lancet Infect Dis, 12, 341, 10.1016/S1473-3099(11)70314-0 Buster, 2009, Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa, Gastroenterology, 137, 2002, 10.1053/j.gastro.2009.08.061 Bonino, 2007, Predicting response to peginterferon-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B, Gut, 56, 699, 10.1136/gut.2005.089722 Lampertico, 2013, Randomised study comparing 48 and 96 weeks peginterferon a-2a therapy in genotype D HBeAg-negative chronic hepatitis B, Gut, 62, 290, 10.1136/gutjnl-2011-301430 Chen, 2014, Extended peginterferon alfa-2a (Pegasys) therapy in Chinese patients with HBeAg-negative chronic hepatitis B, J Med Virol, 86, 1705, 10.1002/jmv.24013 Sonneveld, 2013, Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels, Hepatology, 58, 872, 10.1002/hep.26436 Rijckborst, 2010, Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels, Hepatology, 52, 454, 10.1002/hep.23722 Thio, 2002, HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS), Lancet, 360, 1921, 10.1016/S0140-6736(02)11913-1 Avihingsanon, 2010, Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV-HBV coinfection in Thailand, Antivir Ther, 15, 917, 10.3851/IMP1645 De Clercq, 2018, Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections, Biochem Pharmacol, 153, 2, 10.1016/j.bcp.2017.11.023 Matthews, 2009, Combination HBV. therapy is linked to greater HBV. suppression in a cohort of lamivudine-experienced DNA HIV/HBV. coinfected individuals, AIDS, 23, 1707, 10.1097/QAD.0b013e32832b43f2 Benhamou, 1999, Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients, Hepatology, 30, 1302, 10.1002/hep.510300525 Lacombe, 2008, Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients, Antivir Ther, 13, 705, 10.1177/135965350801300510 Yang, 2015, Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients, World J Gastroenterol, 21, 2746, 10.3748/wjg.v21.i9.2746 Jia, 2018, High prevalence of HBV lamivudine-resistant mutations in HBV/HIV co-infected patients on antiretroviral therapy in the area with the highest prevalence of HIV/HBV Co-Infection in China, Intervirology, 61, 123, 10.1159/000493797 McMahon, 2007, The HBV drug entecavir - Effects on HIV-1 replication and resistance, N Engl J Med, 356, 2614, 10.1056/NEJMoa067710 Pessôa, 2008, Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy, AIDS, 22, 1779, 10.1097/QAD.0b013e32830b3ab5 Gish, 2017, Reactivation of Hepatitis B Virus After Treatment with Direct Acting Antivirals for Hepatitis C: What You Need to Know Liu, 2018, Efficacy of ledipasvir and sofosbuvir treatment of HCV infection in patients coinfected with HBV, Gastroenterology, 154, 989, 10.1053/j.gastro.2017.11.011 Tyson, 2013, Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients, Hepatology, 58, 538, 10.1002/hep.26400 Bini, 2010, Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: Prevalence, racial/ethnic differences, and viral interactions, Hepatology, 51, 759 Bersoff-Matcha, 2017, Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: A review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System, Ann Intern Med, 166, 792, 10.7326/M17-0377 Wang, 2017, Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents, Clin Gastroenterol Hepatol, 15, 132, 10.1016/j.cgh.2016.06.023 Gane, 2016, Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV, Antivir Ther, 21, 605, 10.3851/IMP3066 Tamori, 2017, Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy, J Viral Hepat, 25, 608, 10.1111/jvh.12840 Reddy, 2015, American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy, Gastroenterology, 148, 215, 10.1053/j.gastro.2014.10.039 Muñóz-Espinosa, 1997, Prevalencia de hepatitis D en una población del Noreste de México y su relación con otros virus, Rev Gastroenterol Mex, 62, 246 Trépo, 2014, Hepatitis B virus infection, Lancet, 384, 2053, 10.1016/S0140-6736(14)60220-8 Organización Mundial de la Salud. Hepatitis D [consultado 3 Ene 2020] Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/hepatitis-d; 8 Julio 2019 Wedemeyer, 2010, Epidemiology, pathogenesis and management of hepatitis D: Update and challenges ahead, Nat Rev Gastroenterol Hepatol, 7, 31, 10.1038/nrgastro.2009.205 Rizzetto, 2012, Epidemiology of hepatitis D, Semin Liver Dis, 32, 211, 10.1055/s-0032-1323626 Gilman, 2019, Chronic hepatitis delta: A state-of-the-art review and new therapies, World J Gastroenterol, 25, 4580, 10.3748/wjg.v25.i32.4580 Alter, 2003, Epidemiology of hepatitis B in Europe and worldwide, J Hepatol, 39, S64, 10.1016/S0168-8278(03)00141-7 Noureddin, 2014, Hepatitis delta: Epidemiology, diagnosis and management 36 years after discovery, Curr Gastroenterol Rep, 16, 365, 10.1007/s11894-013-0365-x Heidrich, 2013, Treatment options for hepatitis delta virus infection, Curr Infect Dis Rep, 15, 31, 10.1007/s11908-012-0307-z Heidrich, 2014, Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta, Hepatology, 60, 87, 10.1002/hep.27102 Castelnau, 2006, Efficacy of peginterferon alpha-2b in chronic hepatitis delta: Relevance of quantitative RTPCR for follow-up, Hepatology, 44, 728, 10.1002/hep.21325 Erhardt, 2006, Treatment of chronic hepatitis delta with pegylated interferon- alpha2b, Liver Int, 26, 805, 10.1111/j.1478-3231.2006.01279.x Niro, 2006, Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta, Hepatology, 44, 713, 10.1002/hep.21296 Wedemeyer, 2011, Peginterferon plus adefovir versus either drug alone for hepatitis delta, N Engl J Med, 364, 322, 10.1056/NEJMoa0912696 Wranke, 2017, Antiviral treatment and liver-related complications in hepatitis delta, Hepatology, 65, 414, 10.1002/hep.28876 Yurdaydin, 2008, Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon, J Viral Hepat, 15, 314, 10.1111/j.1365-2893.2007.00936.x Goyal, 2015, Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis, Indian J Gastroenterol, 34, 286, 10.1007/s12664-015-0576-1 Wang, 2016, Entecavir for patients with hepatitis B decompensated cirrhosis in China: A meta-analysis, Sci Rep, 6, 32722, 10.1038/srep32722 Zhang, 2015, The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: A meta-analysis, Ann Hepatol, 14, 150, 10.1016/S1665-2681(19)30776-8 Miquel, 2013, Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice, Ann Hepatol, 12, 205, 10.1016/S1665-2681(19)31358-4 Oh, 2017, Can we trust safety of tenofovir disoproxil in patients with decompensated cirrhosis?, Gut Liver, 11, 743, 10.5009/gnl17401 Singal, 2012, Meta-analysis: Oral antiviral agents in adults with decompensated hepatitis B virus cirrhosis, Aliment Pharmacol Ther, 35, 674, 10.1111/j.1365-2036.2011.04990.x Liaw, 2011, Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, Hepatology, 53, 62, 10.1002/hep.23952 Lee, 2017, Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis, World J Gastroenterol, 23, 2396, 10.3748/wjg.v23.i13.2396 Verna, 2018, Updated hepatitis B guidance: Implications for liver transplant patients, Liver Transpl, 24, 465, 10.1002/lt.25037 2012, EASL-EORTC Clinical practice guidelines: Management of hepatocellular carcinoma, J Hepatol., 56, 908, 10.1016/j.jhep.2011.12.001 Montoliu, 2010, Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites, Clin Gastroenterol Hepatol, 8, 616, 10.1016/j.cgh.2010.03.029 Patel, 2015, Bone disease in cirrhosis, Clin Liv Dis (Hoboken), 6, 96, 10.1002/cld.498 Custodio, 2016, Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment, Antimicrob Agents Chemother, 60, 5135, 10.1128/AAC.00005-16 Arribas, 2017, Brief Report: Randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E/C/F) for initial HIV-1 treatment: Week 144 results, J Acquir Immune Defic Synd, 75, 211, 10.1097/QAI.0000000000001350 Raffi, 2017, Brief report: Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults, J Acquir Immune Defic Syndr, 75, 226, 10.1097/QAI.0000000000001344 Chan, 2016, Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial, Lancet Gastroenterol Hepatol, 1, 185, 10.1016/S2468-1253(16)30024-3 Agarwal, 2018, 96?weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection, J Hepatol, 68, 672, 10.1016/j.jhep.2017.11.039 Seto, 2018, Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 years in patients with chronic HBV infection, Clin Gastroenterol Hepatol, S1542–3565, 30633 Fox, 2011, Individualizing hepatitis B infection prophylaxis in liver transplant recipients, J Hepatol, 55, 507, 10.1016/j.jhep.2011.04.002 2016, EASL Clinical Practice Guidelines: Liver transplantation, J Hepatol., 64, 433, 10.1016/j.jhep.2015.10.006 Samuel, 1991, Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients, Lancet, 337, 813, 10.1016/0140-6736(91)92515-4 McGory, 1996, Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization, Transplantation, 61, 1358, 10.1097/00007890-199605150-00013 Terrault, 1996, Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin, Hepatology, 24, 1327, 10.1002/hep.510240601 Devlin, 1994, Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients, J Hepatol, 21, 204, 10.1016/S0168-8278(05)80396-4 Lauchart, 1987, Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts, Transplant Proc, 19, 4051 Roche, 2015, Rational basis for optimizing short and long-term hepatitis B virus prophylaxis post liver transplantation: Role of hepatitis B immune globulin, Transplantation, 99, 1321, 10.1097/TP.0000000000000777 Anselmo, 2002, New era of liver transplantation for hepatitis B: A 17-year single-center experience, Ann Surg, 235, 611, 10.1097/00000658-200205000-00002 Zheng, 2006, Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis, Liver Transpl, 12, 253, 10.1002/lt.20701 Akyildiz, 2007, Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis, J Gastroenterol Hepatol, 22, 2130, 10.1111/j.1440-1746.2006.04609.x Gane, 2007, Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation, Gastroenterology, 132, 931, 10.1053/j.gastro.2007.01.005 Jiang, 2013, prophylaxis using lamivudine and individualized low-dose hepatitis B immunoglobulin in living donor liver transplantation, Transplant Proc, 45, 2326, 10.1016/j.transproceed.2013.03.028 Xi, 2009, The role of entecavir in preventing hepatitis B recurrence after liver transplantation, J Dig Dis, 10, 321, 10.1111/j.1751-2980.2009.00403.x Jiang, 2010, Prophylaxis against hepatitis B recurrence post-transplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin, Am J Transplant, 10, 1861, 10.1111/j.1600-6143.2010.03208.x Cai, 2012, Clinical study on prevention of HBV re-infection by entecavir after liver transplantation, Clin Transplant, 26, 208, 10.1111/j.1399-0012.2011.01448.x Di Costanzo, 2013, Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: An open single-arm prospective study, Am J Transplant, 13, 348, 10.1111/j.1600-6143.2012.04319.x Hu, 2014, Section 14 Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation, Transplantation, 97, S53, 10.1097/01.tp.0000446278.43804.f9 Fung, 2017, Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years, Hepatology, 66, 1036, 10.1002/hep.29191 Buti, 2003, A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation, J Hepatol, 38, 811, 10.1016/S0168-8278(03)00087-4 Nath, 2006, prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy, Clin Transplant, 20, 206, 10.1111/j.1399-0012.2005.00467.x Buti, 2007, Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence, Transplantation, 84, 650, 10.1097/01.tp.0000277289.23677.0a Wong, 2007, Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy, Liver Transpl, 13, 374, 10.1002/lt.21041 Neff, 2007, Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin, Dig Dis Sci, 52, 2497, 10.1007/s10620-006-9658-3 Angus, 2008, A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis, Hepatology., 48, 1460, 10.1002/hep.22524 Saab, 2011, Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy, Am J Transplant, 11, 511, 10.1111/j.1600-6143.2010.03416.x Lenci, 2011, Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence, J Hepatol, 55, 587, 10.1016/j.jhep.2010.12.036 Teperman, 2013, Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation, Liver Transpl, 19, 594, 10.1002/lt.23628 Gane, 2013, Combination lamivudine plus adefovir without HBIG is safe and effective prophylaxis against HBV recurrence in HBsAg+ liver transplant candidates, Liver Transpl, 19, 268, 10.1002/lt.23600 Yi, 2013, Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin, J Gastroenterol, 48, 1401, 10.1007/s00535-013-0761-x Tanaka, 2014, One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation, Can J Gastroenterol Hepatol, 28, 41, 10.1155/2014/839014 Aygen, 2018, Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report, Turk J Gastroenterol, 29, 259, 10.5152/tjg.2018.18263 Perrillo, 2015, Hepatitis B reactivation from immunosuppressive drug therapy: A global menace, Clin Liver Dis (Hoboken), 5, 39, 10.1002/cld.448 Perrillo, 2015, American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy, Gastroenterology, 148, 221, 10.1053/j.gastro.2014.10.038 Huang, 2013, Randomized controlled trial of entecavir prophylaxis for rituximab associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B, J Clin Oncol, 31, 2765, 10.1200/JCO.2012.48.5938 Tran, 2016, Hepatitis B in pregnancy, Clin Infect Dis, 62, S314, 10.1093/cid/ciw092 Lee, 2006, Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers, Cochrane Database Syst Rev, CD004790 Nelson, 2014, Prevention of perinatal hepatitis B virus transmission, J Pediatric Infect Dis Soc, 3, S7, 10.1093/jpids/piu064 Schillie, 2013, Seroprotection after recombinant hepatitis B vaccination among newborn infants: A review, Vaccine, 31, 2506, 10.1016/j.vaccine.2012.12.012 Pan, 2012, An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus, Clin J Gastroenterol Hepatol, 10, 452, 10.1016/j.cgh.2011.10.041 Pan, 2016, Tenofovir to prevent hepatitis B transmission in mothers with high viral load, N Engl J Med, 374, 2324, 10.1056/NEJMoa1508660 Terrault, 2016, AASLD guidelines for treatment of chronic hepatitis B, Hepatology, 63, 261, 10.1002/hep.28156 Wong, 2018, Review article: Long-term safety of oral anti-viral treatment for chronic hepatitis B, Aliment Pharmacol Ther, 47, 730, 10.1111/apt.14497 Han, 2017, The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta-analysis, Int Immunopharmacol, 42, 168, 10.1016/j.intimp.2016.11.022 Viganò, 2019, Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir, Liver Int, 39, 484, 10.1111/liv.14017